As of December 31, 2023, Zentalis had cash, cash equivalents and marketable securities of $482.9 million. The Company believes that its existing cash, cash equivalents and marketable securities as of December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements into 2026. The December 31, 2023 cash, cash equivalents and marketable securities balance does not reflect the up-front payment from Immunome of $35 million in cash and Immunome stock, which was received in January 2024, as the Company’s agreement was executed and announced in January 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZNTL:
- Zentalis Pharmaceuticals Updates Bylaws for Enhanced Governance
- Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Immunome initiated with an Outperform at Leerink
- Zentalis Pharmaceuticals Issues Regulation FD Disclosure Statement
